Skip to main content

Table 2 Toxicities

From: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

 

No. of Patients (%)

 
 

Grade 1

Grade 2

Grade 3

Grade 4

Hematologic event

    

Neutropenia

2 (7.4)

3 (11.1)

2 (7.4)

0 (0.0)

Febrile neutropenia

-

-

0 (0.0)

0 (0.0)

Thrombocytopenia

12 (44.4)

1 (3.7)

3 (11.1)

0 (0.0)

Anemia

10 (37.0)

5 (18.5)

2 (7.4)

0 (0.0)

Nonhematologic event

    

Asthenia

7 (25.9)

11 (40.7)

4 (14.8)

0 (0.0)

Nausea/Vomiting

10 (37.0)

6 (22.2)

0 (0.0)

0 (0.0)

Mucitis

3 (11.1)

0 (0.0)

0 (0.0)

0 (0.0)

Diarrhea

6 (22.2)

4 (14.8)

0 (0.0)

0 (0.0)

Sensory neuropathy

10 (37.0)

2 (7.4)

2 (7.4)

0 (0.0)

  1. Toxicities were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0).